Ownership Submission
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
Eansor Norman David
   2. Issuer Name and Ticker or Trading Symbol
BIO-TECHNE Corp [TECH] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
SVP - Novus Biologicals
(Last)
(First)
(Middle)
8100 SOUTHPARK WAY, A-8		 3. Date of Earliest Transaction (Month/Day/Year)
10/30/2017
(Street)

LITTLETON, CO 80120		 4. If Amendment, Date Original Filed(Month/Day/Year)
 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)		 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)		 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)		 6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)		 7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock               3,402 D  

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)		 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)		 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)		 6. Date Exercisable and Expiration Date
(Month/Day/Year)		 7. Title and Amount of Underlying Securities
(Instr. 3 and 4)		 8. Price of Derivative Security
(Instr. 5)		 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)		 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)		 11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (1) 10/26/2017   A   2,174     (2)   (2) Common Stock 2,174 $ 0 2,174 D  
Stock Options (Right to buy) $ 125.05 10/26/2017   A   11,982     (2) 08/09/2024 Common Stock 11,982 $ 0 11,982 D  
Stock Options (Right to buy) $ 125.05 10/26/2017   A   15,976     (3) 08/09/2024 Common Stock 15,976 $ 0 15,976 D  
Restricted Stock Units (1)               (4)   (4) Common Stock 1,500   1,500 D  
Restricted Stock Units (1)               (5)   (5) Common Stock 2,287   2,287 D  
Stock Option (Right to Buy) $ 108.49               (6) 08/07/2022 Common Stock 12,500   12,500 D  
Stock Option (Right to Buy) $ 108.49               (4) 08/07/2022 Common Stock 9,375   9,375 D  
Stock Option (Right to Buy) $ 94.35               (7) 08/12/2021 Common Stock 15,000   15,000 D  
Stock Options (Right to buy) $ 106.59               (8) 08/18/2023 Common Stock 18,819   18,819 D  
Stock Options (Right to buy) $ 106.59               (5) 08/18/2023 Common Stock 14,114   14,114 D  

Reporting Owners

Reporting Owner Name / Address Relationships
 Director  10% Owner  Officer  Other
Eansor Norman David
8100 SOUTHPARK WAY, A-8
LITTLETON, CO 80120		       SVP - Novus Biologicals  

Signatures

 /s/ Brenda S. Furlow, attorney in fact for David N. Eansor pursuant to Power of Attorney filed here with   10/30/2017
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
(2) Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
(3) Vest 3,994 shares on each 8/9/2018, 8/9/2019, 8/9/2020, 8/9/2021
(4) Vests in full or in part on 8/7/18 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
(5) Vests in full or in part on 8/18/19 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
(6) 3,125 shares vest on each of 8/7/16, 8/7/17, 8/7/18 and 8/7/19.
(7) 3,750 shares vest on each of 8/12/15, 8/12/16, 8/12/17 and 8/12/18.
(8) Vests 4,705 shares on 8/18/17, 8/18/18, and 8/18/19 and 4,704 shares on 8/18/20.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.